drugset / Trial / NCT02045056

Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease

NCT02045056

Phase 0 Completed 72 enrolled Gregory Jicha, 323-5550
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to assess the safety and efficacy of gemfibrozil in modulating microRNA-107 levels for the prevention of Alzheimer's disease in subjects with intact cognition and mild cognitive impairment

Timeline

Start
2014-05
Primary completion
2018-06-30
Completion
2019-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemfibrozil Small molecule 600 mg Oral

Indications